



# Q1 2022 BUSINESS UPDATE

MAY 10, 2022



# DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

# STRONG RESULTS & FOCUS ON KEY PRIORITIES

Q1 2022.  
BUSINESS UPDATE SUMMARY.

2

NEW programs under contract

158

cumulative programs under contract

6

NEW programs started

84

cumulative programs started

1


MOLECULE entered the clinic

>\$780M


in cash, cash equivalents & marketable securities



# THE BEST CAPABILITIES IN THE WORLD FROM TARGET TO IND



- ✓ 2x faster
- ✓ solve the unsolvable
- ✓ highest quality
- ✓ unprecedented scale





# DEAL STRUCTURES THAT CAPTURE DOWNSTREAM VALUE

We expanded our existing partnership with Empirico to 7 targets, and the new agreement provides us with the option, on a program-by-program basis, to co-invest in preclinical and clinical development in exchange for a greater ownership stake in the program. In the event we continue to co-invest, we will maintain a 50% interest in each program.



---

**7** **targets**  
multi-year


 multiple  
indications



# A DIVERSE PANEL OF CD3 ANTIBODIES TO CREATE NEW CANCER THERAPIES

We used our technology to find hundreds of CD3-binding antibodies that can be combined to create precision cancer therapies.

We then used our clinically-validated bispecifics platform, OrthoMab™ to pair the CD3-binding antibodies with a single EGFR-binding arm and confirm their function.



**Diverse**



**Developable**



**Validated**



# Q1 2022

FINANCIALS UPDATE



# Strong portfolio growth.

Total # of


**Programs Under Contract 158**



Total # of

**Discovery Partners 36**

Cumulative # of


**Program Starts**



 - WITHOUT downstream participation  
 + WITH downstream participation

Cumulative # of






**Molecules in the Clinic**



Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.




# 6 molecules in the clinic, 2 authorized for emergency use.

MOLECULE	STAGE	PARTNER	THERAPEUTIC AREA	PROGRAM TYPE
<b>bamlanivimab</b> (LY-CoV555)	Marketed, Emergency Use Authorization (EUA)		<ul style="list-style-type: none"> <li>infectious disease - COVID-19</li> </ul>	AbCellera Discovery Partnership
<b>bebtelovimab</b> (LY-CoV1404)	Marketed, Emergency Use Authorization (EUA)		<ul style="list-style-type: none"> <li>infectious disease - COVID-19</li> </ul>	
<b>NBL-012</b>	Phase I		<ul style="list-style-type: none"> <li>dermatology</li> <li>gastrointestinal disease</li> <li>immunology</li> </ul>	Trianni License
<b>NBL-015</b>	IND approved		<ul style="list-style-type: none"> <li>oncology</li> </ul>	
<b>NEW undisclosed</b>	IND approved	undisclosed	<ul style="list-style-type: none"> <li>undisclosed</li> </ul>	
<b>IVX-01</b>	Clinical field study		<ul style="list-style-type: none"> <li>animal health</li> </ul>	AbCellera Discovery Partnership



# \$316.5M total revenue, driven by royalties for bamlanivimab and bebtelovimab.







# Operating expenses reflect strengthening of the platform.

## Operating Expenses USD


### RESEARCH & DEVELOPMENT



### SALES & MARKETING



### GENERAL & ADMIN







Net earnings of \$168.6M: equivalent to \$0.59 (basic) and \$0.54 (diluted) per share.

Earnings USD


### NET EARNINGS



### EARNINGS PER SHARE: BASIC




### EARNINGS PER SHARE: DILUTED





# Over \$780 million in total cash, equivalents, and marketable securities.





THANK  
YOU

